Immunome (IMNM, $14.72) was a top loser over the last three months, falling -3 to $14.72 per share. A.I.dvisor analyzed 908 stocks in the Biotechnology Industry for the 3-month period ending May 14, 2024, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.